Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:30:39.024Z.
Calculation as of: 2026-10-06T13:30:39.024Z.
Quote observation: 2026-10-06T13:30:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d465a3cb364884174ea279f6e96e1b331d3038a7942601b23d7c9becb19c45da
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Avalyn Pharma Inc. Common Stock
Market Cap
$1.20B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.22B
EV/EBIT Ratio
59.54x
TTM Avg
63.01x
3Y Avg
63.01x
5Y Avg
63.01x
Market Cap
$1.22B
EV/EBIT Ratio
19.15x
TTM Avg
131.59x
3Y Avg
131.59x
5Y Avg
72.61x
Market Cap
$1.17B
EV/EBIT Ratio
17.53x
TTM Avg
14.99x
3Y Avg
31.51x
5Y Avg
159.52x
Market Cap
$1.14B
EV/EBIT Ratio
237.98x
TTM Avg
98.35x
3Y Avg
222.12x
5Y Avg
246.60x
Market Cap
$1.15B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
EV/EBIT Ratio
N/A
TTM Avg
59.55x
3Y Avg
59.55x
5Y Avg
78.29x
Market Cap
$1.12B
EV/EBIT Ratio
13.90x
TTM Avg
11.45x
3Y Avg
12.41x
5Y Avg
16.01x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | 59.54x | 63.01x | 63.01x | 63.01x |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 19.15x | 131.59x | 131.59x | 72.61x |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.17B | 17.53x | 14.99x | 31.51x | 159.52x |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.26B | N/A | N/A | N/A | N/A |
| Harrow Health, Inc. (HROW)vs › | $1.14B | 237.98x | 98.35x | 222.12x | 246.60x |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.15B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A | 59.55x | 59.55x | 78.29x |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 13.90x | 11.45x | 12.41x | 16.01x |
| IRadimed Corporation (IRMD)vs › | $1.11B | 37.97x | 43.03x | 33.26x | 35.95x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
